Rasagiline is a monoamine oxidase type-B inhibitor used as monotherapy or in addition to levodopa in the treatment of Parkinson's disease. Once daily administration of rasagiline makes it easy to use, and allows good compliance by patients and adherence to therapy. Several multicenter studies have noted the effectiveness of rasagiline on both motor and non-motor symptoms, which require a complex pharmacologic approach, such as cognitive disorders. A recent study also reported a rapid action of rasagiline on motor symptoms. Positive findings have been highlighted by an economic model study. This review analyzes the main studies of rasagiline, with particular attention to the effectiveness of the drug on motor symptoms.
INTRODUCTION
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the selective degeneration of dopaminergic neurons in the substantia nigra pars compacta that determines the presence of motor symptoms, namely bradykinesia, muscle rigidity, and resting tremor. However, the M. Pistacchi and S. Zambito Marsala contributed equally to the article. pathology of the disease often becomes complicated by the presence of non-motor symptoms, which require complex drug treatment, including autonomic disorders, postural instability, bowel and bladder dysfunction, mental disorders (anxiety, apathy, dementia, depression, psychosis), pain, and sleep disorders (daily hypersomnolence, nocturnal akinesia, restless legs syndrome).
The majority of drug therapies used in PD aim at increasing the level of striatal dopamine. This can be achieved by administering levodopa, directly stimulating post-synaptic dopamine receptors with dopamine agonists (DA).
Another therapeutic strategy involves inhibiting the enzymes responsible for degrading levodopa [1, 2] .
The enzyme monoamine oxidase (MAO) is a protein of the outer mitochondrial membrane that metabolizes neurotransmitters in the brain and in other tissues. Its inhibition can potentially elevate levels of the major metabolites of neurotransmitters such as dopamine and tyramine [3] . MAO is classified as MAO-A and MAO-B: MAO-A is found mostly in the intestinal tract but also in some presynaptic neurons in the brain, while MAO-B is predominant in the brain, mainly localized in glial cells near the dopaminergic synapses, and regulates both the releasable stores and free levels of free intra-neuronal dopamine [4, 5] .
Rasagiline is a selective and irreversible inhibitor of MAO-B, which can be used either as monotherapy or as adjunctive therapy to levodopa or to DA agents in PD [6] . It is five times more potent than selegiline in inhibiting the activity of MAO-B after repeated administration [7] . In healthy volunteers who received a single oral dose of 1, 2, 5, or 10 mg rasagiline, maximum inhibition of MAO-B platelet activity, considered to be a marker of brain MAO-B, was observed 1 h after administration [8] . Significant intergroup differences in MAO-B platelet inhibition favoring rasagiline 2, 5, and 10 mg/day were evident 2 h after the first dose, while multiple doses of rasagiline 2 mg per day showed [99% MAO-B inhibition by day 6 [8] . For all multiple doses of rasagiline, maximum inhibition of MAO-B platelet activity was maintained up to 24 h after the last administration, and activity returned to baseline levels 2 weeks after the cessation of therapy. In patients with PD, MAO-B platelet activity was completely inhibited following 7 days treatment with 0.5, 1, or 2 mg/day rasagiline [9] .
This article reviews the main pharmacologic, pharmacodynamic, and pharmacokinetic
properties of rasagiline in the treatment of PD.
MATERIALS AND METHODS
We identified pertinent studies by searching Medline-Pubmed databases (1992-2013) using the key words: rasagiline, MAO-B inhibitors, and Parkinson's disease. We included articles reporting on double-blind, placebo-controlled,
randomized studies, open-label randomized studies, controlled studies, and pharmacologic studies. We also considered review articles and research support studies. Articles selected for the review specifically described results of randomized double-blind clinical studies, and long-term clinical trials.
The authors independently selected results focusing on the final outcome measurements, different scales used on clinical or pharmacologic efficacy, statistical significance, and adverse events. Each article was independently reviewed by authors indicating the major interesting data in the field of effectiveness and safety, and disagreements were solved by discussion.
We also followed the indications of the PRISMA statement: multicenter double-blind, placebo-controlled parallel group, delayed start/ clinical trial, double-blind trial, post hoc analysis, open-label extension, post-marketing observational open-label studies [10] .
TEMPO Study
The TEMPO study was a multicenter, randomized, double-blind placebo-controlled study of rasagiline in 404 patients with earlystage PD [11] . Patients were randomized to receive rasagiline at a dose of 1 or 2 mg/day or placebo. An initial titration period of 1 week was followed by a maintenance period of 25 weeks. The primary measure of efficacy was the change in total Unified Parkinson's Disease Rating Scale (UPDRS) score [12] between baseline and 26 weeks of treatment. Secondary end points were: cognitive deficits; difficulties with activities of daily living (ADL) [13, 14] ; evaluation of motor subscales of the UPDRS, as well as subscores based on symptoms (tremor, rigidity, bradykinesia, instability/gait, and postural changes) [15] . Other secondary variables included changes to the scale of Hoehn and Yahr (H&Y) [16] , the Schwab and England ADL scale [17] , the Beck Depression Inventory score [18] , the Mini Mental State Examination (MMSE) score [19] , timed motor test scores [20] , and quality of life (QoL) on the PD Quality of Life (PDQUALIF) scale [21] . Patients who experienced a worsening of scores, \3 units in their total UPDRS score from baseline to 26 weeks were classified as responders.
Calculation of the Power of the Study
According to the Bonferroni method [22] , 120 patients per group (360 in total) were required to give a power of between 81% and 93% to detect a significant effect of one or both dosages of rasagiline, when treatment with 2 mg/day rasagiline resulted in an improvement of 3 points in UPDRS scores compared with placebo, and treatment with 1 mg/day rasagiline resulted in an improvement in UPDRS scores of between 0 and 3 units.
Results
Mean [standard deviation (SD)] UPDRS scores at 26 weeks were 24.8 (12. 3) in the rasagiline 1 mg/day group, 26.6 (11.8) in the rasagiline 2 mg/day group, and 28.4 (14. 3) in the placebo group [11] . The unadjusted changes from baseline were: 0.1 (6.8), 0.7 (5.8) , and 3.9 (7.5) in the rasagiline 1 mg/day, 2 mg/day, and placebo groups, respectively. Both active treatment groups showed benefits compared with the placebo group (P\0.001 for each comparison).
The analysis of responders who showed a change in UPDRS total score \3 units also demonstrated the effects of each active treatment (placebo, 49%; rasagiline 1 mg/day, 66%, and rasagiline 2 mg/day, 67%, with P = 0.004 and P = 0.001 for the 1 and 2 mg rasagiline group vs. placebo, respectively respectively [11] .
The Kaplan-Meier analysis showed no statistically significant differences in the start of adjunctive therapy among the three treatment groups. Both groups treated with rasagiline showed significant improvement in PDQUALIF scores compared with placebo. The exploratory analysis suggested that the benefit occurred mainly in the measurement of self-image/sexuality subscales, with negligible effects on the social role subscale. Significant benefits were noted in responses to one question comparing present PD symptoms with those experienced 3 months earlier [11] . Adverse events (AEs) were no more frequent in the active treatment groups than in the placebo group. The most commonly observed AEs were infection (16%) and headache (12%).
Other AEs occurred with a frequency of \10%. There were no statistically significant differences in the rates of early termination between the treatment groups and the placebo group [11] . Twenty serious AEs (defined as hospitalizations or new malignancies) occurred during the study: four in the placebo group, six in the 1 mg/day rasagiline group, and ten in the 2 mg/day rasagiline group [11] . One patient in the 2 mg/day rasagiline group experienced two serious AEs (hospitalization for depression and delirium).
PRESTO Study
The PRESTO study was a multicenter, randomized, placebo-controlled double-blind phase III study in 472 patients with PD who experienced at least 2.5 h of being 'off' (poor motor function) every day despite optimized treatment with levodopa [23] .
Patients were randomized to receive rasagiline at a dose of 1 or 0.5 mg/day, or placebo. Eligible patients were aged [30 years with idiopathic PD and were in a modified HY stage of \5 in the 'off' state. Patients monitored their blood pressure before and after the main meal of the day for 7 days before the baseline, and week 3, and week 26 visits.
The primary efficacy end point was the change from baseline in mean total daily 'off' time measured through patient diaries, and the average was considered during the treatment period (from week 6, 14, and 26). The secondary end point was the investigator's clinical global impression of improvement, measured on a global scale that included 7 points ranging from 'significantly improved' to 'no change' to 'significantly worsened'., as well as changes from baseline in the UPDRS-ADL scale, and quality of life as measured by the PDQUALIF scale. Additional end points were: changes from baseline in the total average daily 'on' and 'off' times on the Schwab and England ADL scale, and in 'on' times on the UPDRS-ADL scale.
The primary statistical analysis included data from all randomized patients provided with the diary (n = 451). To evaluate the effect of patients who withdrew, the analyses were repeated using only patients who completed the study (n = 414) and patients who completed all procedures according to the protocol (n = 359). The measures of secondary end points were made in the same way as the primary end point. The most common deviations were related to early termination (12%), less than six acceptable daily diaries (10%, mainly in patients who left the study prematurely), and change in daily levodopa or other anti-PD dosage by [20% from baseline during the last 20 weeks of the study (4%) [23] .
Compliance to treatment was high, as demonstrated by counting pills, with 95% of patients treated with at least 90% of the planned doses. Between baseline and week 26, patients treated with placebo decreased their mean ± SD daily dosage of levodopa from 12 ± 142 mg, while patients treated with 0.5 mg/day rasagiline decreased their dosages by 32 ± 122 mg, and patients treated with 1 mg per rasagiline decreased administration of levodopa by approximately 36 ± 133 mg. The majority of patients were taking other antiparkinsonian drugs, including DA, entacapone, and amantadine [23] .
Results
During the treatment period, the average total daily 'off' time decreased from baseline by 1.85 h (29%) in patients treated with 1 mg/day per day rasagiline, 1.41 h (23%) with 0.5 mg/ day rasagiline, and 0.91 h (15%) with placebo.
Patients treated with 1 mg/day rasagiline had 0.94 h [95% confidence interval (CI) 0.51-1.36,
P\0
.001] less 'off' time a day compared with placebo. Patients treated with 0.5 mg/day rasagiline had 0.49 h (95% CI 0.08-0.91, P = 0.02) less 'off' time compared with placebo. The differences compared to baseline between the groups were maintained throughout the treatment period. There was no difference in treatment effects between the study centers (P = 0.58). Compared with placebo, the clinical global impression, UPDRS-ADL score during 'off' time, and UPDRS-motor score during 'on' time improved significantly during treatment with rasagiline [23] .
Quality of life, as measured by the PDQUALIF score, showed a trend toward improvement in patients treated with 0.5 mg/ day rasagiline (P = 0.07), but not with 1 mg/day rasagiline. The social subscale of the PDQUALIF scale showed a benefit for both rasagiline doses compared with placebo, the outlook subscale showed a benefit for the 0.5 mg/day dose, while the function, image, independence, sleep, and urinary subscales showed no difference compared with placebo. Exploratory analyses showed a significant increase in the amount of time 'on' with both doses of rasagiline, corresponding to reductions in the overall time 'off'. In the group treated with 0.5 mg/ day rasagiline, there was a greater period of time without troublesome dyskinesia. In the group treated with rasagiline 1 mg/day, 32% of the increase in 'on' time included the presence of troublesome dyskinesias. The rasagiline 1 mg/ day group showed a significant improvement in the Schwab and England ADL scale during 'off' times (P = 0.02), but a dose of 0.5 mg/day did not produce the same result. The post hoc analysis of UPDRS subscores during the time 'on' showed a significant improvement in rigidity, bradykinesia, and tremor in patients treated with 1 mg/day rasagiline, and in postural instability and in gait and tremor in patients treated with the 0.5 mg/day dose [23] .
Adverse events were reported in 87% of patients treated with placebo, 91% receiving 0.5 mg/day rasagiline, and 95% receiving 1 mg/ day rasagiline.
These tended to be gastrointestinal AEs and appeared to be dose related. Dyskinesias were reported as an AE in 10% of placebo-treated patients, and in 18% of patients treated with either dose of rasagiline (P = 0.03 for combined rasagiline groups vs. placebo). Balance difficulties occurred more often in patients treated with rasagiline, but they did not appear to be dose related. Depression was significantly less common in patients treated with 0.5 mg rasagiline compared with placebo (P = 0.04).
There were 22 serious AEs in 14 patients treated with placebo, 42 in 21 patients treated with 0.5 mg rasagiline, and 27 in 18 patients treated with 1 mg rasagiline.
The most common serious AEs were related to accidental injury (n = 6), arthritis, worsening PD, melanoma, stroke (n = 3), and urinary tract infections (n = 3), and none was significantly more common in patients treated with rasagiline than with placebo.
Rasagiline did not have negative effects on blood pressure or heart rate. During treatment, dermatologic examinations revealed three patients with melanoma (1 in the 0.5 mg rasagiline group and 2 patients in the 1 mg rasagiline group). One additional patient was Neurol Ther (2014) 3:41- 66 45 identified as having a melanoma before starting the study [23] .
LARGO Study
The LARGO study was a randomized, doubleblind, multicenter 18-week phase III trial of rasagiline in levodopa-treated patients with PD and motor fluctuations [24] . In total, 687 outpatients were randomly assigned to receive oral rasagiline 1 mg/day (n = 231), entacapone 200 mg with every levodopa dose (n = 227)), or placebo (n = 229). As a comparator, this trial also included an adjunct entacapone [25] [26] [27] [28] .
The primary outcome measure was change in total daily 'off' time. The secondary outcome measures included the clinical global improvement (CGI) score [29] and the UPDRS scores. A post hoc analysis of the primary and secondary efficacy variables was undertaken to assess treatment effects stratified by age ([70 or \70 years) and according to whether patients received concomitant treatment with DA.
Additional exploratory end points included: responder analysis, mean change from baseline in the 'on' state with or without troublesome dyskinesia, and UPDRS-dyskinesia.
Results
There were no major differences between study groups. Dopamine agonists were the most common class of concomitant drugs for PD (about 60%, i.e., 130-141 patients in each group). Amantadine and anticholinergic drugs were the other most frequently used therapies with rasagiline. Rasagiline reduced the mean total daily 'off' time from baseline (primary end point) by more than 1 h, almost three times more than the reduction with placebo (P = 0.0001) and increased daily 'on' time without troublesome dyskinesia (0.85 h vs. placebo 0.03 h; P = 0.0005). This effect was already evident at the first efficacy assessment (week 6, adjusted mean change -1.31 vs. -0.27 for placebo; P = 0.0001). Additionally, patients' diaries revealed an accompanying increase in daily 'on' time with the active treatments, most of which was without troublesome dyskinesia.
No change in the duration of 'on' time with troublesome dyskinesia was recorded. Responder analysis also supported these findings. This improvement in drug efficacy was accompanied by a small, but significant reduction in levodopa dose with rasagiline (-24 mg/day) compared with a 5 mg/day increase with placebo (P = 0.0003 vs. placebo).
At week 18, the clinical global improvement score improved compared with placebo by 0.49 units for rasagiline (P = 0.0001). The two UPDRS secondary end points were significantly improved by rasagiline and entacapone:
UPDRS-motor ('on' state) and UPDRS-ADL ('off' state). The three UPDRS exploratory subscores measuring dopa-responsive symptoms (tremor, rigidity, and bradykinesia) also significantly improved on rasagiline.
UPDRS-dyskinesia scores showed no significant increase when patients were receiving either active treatment compared with placebo.
Three other UPDRS subscores were significantly improved by rasagiline, but not by entacapone: UPDRS-PIGD, UPDRS-freezing (in patients who, at baseline, experienced freezing when walking), and UPDRS-motor in the practically defined 'off' state.
Results of primary efficacy analysis were similar in both active treatment groups in old ([70 years) and young (\70 years) patients. For patients receiving rasagiline, the difference versus that of placebo was -0.79 h in the young group, and -0.76 h in the old group, indicating similarity between the strata (P = 0.961). Significant mean improvements in CGI scores were recorded (-0.86 rasagiline; P = 0.0001). Changes in UPDRS-ADL scores also significantly improved during 'off' time (-1.71 vs. placebo; P = 0.0001) and motor function during 'on' time (-2.94 vs. placebo; P = 0.0001). Rasagiline was well tolerated with a safety profile similar to that of placebo. Importantly, the drug was equally well tolerated in the oldage group (C70 years) with no evidence of increased hallucinations, a common concern with DA. time. PRESTO and LARGO data were pooled to evaluate the primary and secondary end points in all patients, and in the subgroup of patients who were receiving only levodopa at baseline [32] . Pooled data were also used to evaluate the effect of rasagiline on cardinal symptoms of PD during 'on' time [33] and included analysis of bradykinesia, rigidity, tremor, postural stability, and gait, using the intent-to-treat (ITT) principle. 

When
Summary
Post hoc analyses of the PRESTO and LARGO trials showed that rasagiline is a good choice as first adjunct therapy in levodopa-treated patients; rasagiline benefits patients with relatively minor motor symptoms suggestive of early 'wearing off'. The well-established benefits of rasagiline on motor function are related to improvement of all of the cardinal symptoms of PD, and rasagiline added to combination therapy with levodopa and DA or levodopa and COMT-I is well tolerated and further improves symptoms in patients with PD experiencing motor fluctuations. Therefore, adding rasagiline to an already optimized dopaminergic treatment regimen in patients with relatively mild motor fluctuations (B4 h/ day at study entry) can reduce mean total daily 'off' time by approximately 25%, whereas total daily 'off' time in placebo-treated patients increased by approximately 7% during the double-blind studies (P\0.01 vs. placebo).
ADAGIO Study
The ADAGIO study was a double-blind, placebocontrolled, delayed-start study, which randomized 1,176 patients with PD at an early stage and not requiring dopimanergic therapy, to receive rasagiline 1 or 2 mg/day for 72 weeks (early-start group) or placebo for 36 weeks followed by rasagiline 1 or 2 mg/day for another 36 weeks (delayed-start group) [34] .
The delayed-start design was used to examine the potential neuroprotective effects of rasagiline in PD. Patients assigned to placebo in phase I who required anti-parkinsonian therapy were included automatically in the active treatment phase (early converters).
The primary analysis of the study included three end points based on the change from baseline in UPDRS scores in the rasagiline versus placebo groups: between the 12th and 32nd week of active treatment; between the 1st and 72nd week of active treatment; and between the 48th and 72nd week of active treatment. The secondary end point of the study was to compare and estimate the changes to UPDRS score at baseline and at the 72nd week in patients treated with rasagiline 1 mg and 2 mg/day.
Results
Overall 1,164 patients were included in the first primary end point analysis, and 996 (85%) were included in the analyses of the second and third primary end points. There were no significant differences among the treatment groups at P\0.001). Rasagiline at a dosage of 2 mg/day did not reach the three primary end points of the study [34] .
Post hoc Analysis
In considering the possibility that the effect of disease modification with rasagiline 2 mg/day may be masked by a mild disease state, the primary and secondary analyses were performed in patients with a UPDRS score[25.5 at baseline [34] . Among patients treated with 2 mg/day rasagiline, the difference in the UPDRS scores from baseline to week 72 of the early-start group and the delayed-start group was significantly higher among patients with baseline UPDRS scores in the highest than among patients with scores in the other three quartiles (P = 0.03).
Therefore, patients in these subgroups can be considered separately. The patients who received 1 or 2 mg/day rasagiline, and who had a baseline score that fell in the highest at baseline did not meet the primary end points [34] .
Safety
There were no significant differences in AEs among the study groups, which were: falls, back pain, nasopharyngitis, arthralgia, headache, musculoskeletal pain, nausea or vomiting, hypertension, orthostatic hypotension, somnolence, and hallucination. One patient in the early-start group who received rasagiline at a dose of 1 mg/day had a melanoma at week 72. No patient had tyramine or serotonin reactions [34] .
Summary
Early treatment with rasagiline at a dose of 1 mg/day provided benefits that were consistent with a possible neuroprotective effect, but early treatment with rasagiline at a dose of 2 mg/day did not. Both doses had beneficial effects on symptoms, as compared to placebo, findings that are similar to those that have been reported previously. Because the two doses were associated with different outcomes, the study results must be interpreted with caution. Patients in the TEMPO study (n = 404) were randomly assigned to initial treatment with rasagiline (early-start group) or placebo for 6 months followed by rasagiline (delayed-onset group). Those 
Results
Of the 404 patients enrolled in the TEMPO study, 266 were randomly assigned to initial treatment with rasagiline 1 or 2 mg, and 138 were randomly assigned to treatment with placebo (delayed-start rasagiline 
Efficacy
Changes from baseline to the last visit in the TEMPO study were assessed using the UPDRS score. For the entire period of observation lasting 6.5 years, the adjusted mean difference in change from baseline, expressed as total UPDRS score, was 2.5 units (SE 1.1) (P = 0.021) in favor of early-onset group compared to treatment with rasagiline in early delayed.
This corresponds to a relative difference in mean percentage change from baseline between groups of 16% (SE 5.7, P = 0.006).
Although the correlation between treatment and time was significant for both analyses (P = 0.0146 for changing UPDRS score and P = 0.0126 for the percentage changes of UPDRS score), the value for the early treatment group was numerically better than delayed onset of treatment in all the scores and this correlation reflects the observed variability in the differences between the group that started treatment early and late-start group including a decrease in differences after 1 year compared to 6 months of therapy and an increase in the difference between the groups after 4 years.
The analysis evaluated at intervals of 6 months revealed less significant deterioration, expressed as a percentage of change in total UPDRS score, in the early-start group at 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P\0.05). Changes in the UPDRS-ADL motor score were better in the early-start group, with mean differences expressed as a percentage of change from baseline between the groups of 11.9% (SE 5.9, P = 0.046) and 39.1% (SE 17.7, P = 0.028), respectively.
Of the 177 patients who remained in the study until the opening of the database, 114
were part of the group treated since the very start of the study, and 63 were part of the group with delayed onset, consistent with the ratio of the original randomization. The average duration of treatment with rasagiline was 5.6 ± 0.4 years for the group at the beginning of treatment and 5.5 ± 0.4 years for the delayed start. The baseline characteristics of the patients who remained in the study until the end of the opening of the database, compared with the ITT population, had longer time from diagnosis to PD and slightly lower than the average total UPDRS score and HY classification. For these 177 patients, the adjusted mean difference in total UPDRS score was 2.42 units (SE ± 1.04, P = 0.0218) in favor of the early-start group, corresponding to an average relative difference in change percentage from baseline of 17% (SE ± 5.4, P = 0.002).
Other Dopaminergic Drugs
The average length of time from baseline to study time to adding an additional dopaminergic treatment was similar for the early-start group and the delayed-start group Similarly, the equivalent dosage of levodopa did Neurol Ther (2014) 3:41- 66 51 not differ significantly in all 6-monthly intervals between the groups.
Motor Complications
For the 211 patients for whom data on fluctuations and dyskinesias were collected, At each visit, the investigator reported the presence of spontaneous AEs and evaluated the possible need for additional therapy.
Results
The average annual rate of progression assessed by the UPDRS for all patients was equal to 1. 
Outcome Measures
Outcome measures, including the change from baseline, were assessed on the Columbia University Rating Scale (CURS) [38] , the UPDRS subscale for fluctuation and daily 'off' time (daily diaries of patients) [12] , and the PD Questionnaire-39 (PDQ-39) [39] . Adverse drug reactions (ADRs) and AEs were also examined, as well as global clinical efficacy and safety.
The evaluations were performed at baseline, at 4 weeks and 4 months. Results were recorded from medical charts of data collection.
The score of the CURS was based on the evaluation of 13 items: 3 classic elements (tremor, rigidity, bradykinesia) and 10 nonmotor symptoms or motor non-classical symptoms (facial expression, seborrhea, drooling, impaired speech, finger dexterity, foot tapping, arising from chair, posture, postural stability, gait disturbance). Severity was assessed as: 0 (normal) to 4 (severe). An enhancement in the CURS scale was defined as a reduction in score of at least 1 point. The UPDRS was calculated from the sequence of four parts UPDRS complications scale, which assesses the predictability, the appearance, and the time spent in the 'off' phase.
QoL was examined using the PD-Q39, which consists of 39 items that can be added together to generate eight subscales, and a total score.
In this analysis, the summed scores could range from 0 (no difficulty) to 100 (maximum difficulty). At the final evaluation at 4 months,
investigators were asked to rate on a global level the efficacy and tolerability of rasagiline as:
(a) very good, (b) good, (c) modest, or (d) poor.
In a post hoc analysis, the overall tolerability assessment was also grouped by age (\70 years; [70 years).
Results
The authors collected data on 754 patients. In total, 545 patients were treated with rasagiline as an adjunctive therapy and 209 patients 
Periods of Time in Daily 'Off'
The time period in daily 'off', as recorded in patient diaries, was examined only in patients receiving combination therapy. The evaluation of efficacy was based on data from the diaries of 203 patients who completed all three phases of the study. During the study, considering a median daily period of time equal to 'off' significantly decreased from 120 to 45 min (P\0.001), with a significant reduction as early as the mid-term (1-4 weeks). 
Evaluation of Overall Effectiveness
Safety and Tolerability
AEs/ADRs were reported by 5/209 monotherapy patients (2%) and 46 Two patients on monotherapy (1%) and 27 patients receiving combination therapy (5%) withdrew from the study due to lack of tolerability. At the final evaluation, the overall tolerability of treatment with rasagiline was assessed by the investigators as good or very good in 193/199 patients in the monotherapy group (97%) and in 474/527 patients in the combination therapy group (90%). The post hoc analysis showed that the tolerability of rasagiline (as monotherapy or in combination therapy) did not seem to be influenced by age and was evaluated as good or very good in 387/420 patients (92%) aged \70 years, and 276/302 patients (91%) aged C70 years.
Switch to Rasagiline Group
The subgroup of patients who switched to rasagiline showed a significant improvement in symptoms between baseline and the final evaluation in both classical and non-classical motor scores (CURS total score, P\0.001;
classical ? nonclassical motor score ? partial non-motor score, P = 0.002), and in the percentage of patients free from 'off' periods during the day (36% vs. 48%, respectively). QoL questionnaires showed that these patients had also benefited from an improvement of 6.5 points in the PDQ-39 total score (P = 0.002) and significant improvements in specific individual PDQ-39 scores in motility (P = 0.01), ADL (P\0.01), emotional score (P\0.05), and 'stigma' (P = 0.001). The tolerability to the 
Results
The magnitude of beneficial effect was similar in monotherapy and adjunct therapy patients.
No significant dopaminergic side effects, tyramine reactions, or interactions with antidepressants were observed in the 12-week trial.
Conclusion
Rasagiline has a measurable beneficial effect on PD symptoms within 1 week of treatment.
Rasagiline has a similar magnitude of benefit in monotherapy and adjunct therapy patients.
Adverse interactions between antidepressants
and rasagiline were not observed in patients in this trial. and in add-on therapy patients, respectively; P = 0.636). Treatment with rasagiline was associated with statistically significant decreases from baseline in mean UPDRS III total score in the overall sample and in the two subgroups (P\0.0001 at week 1 and week 4). The mean (±SD) change from baseline in the overall sample was -6.7 ± 5.3 (95% CI -7.8 to -5.7) at week 1, and -8.9 ± 6.1 (95% CI -10.1 to -7.7) at week 4. Changes from baseline were -6.7 ± 4.4 (95% CI -8.4 to -4.9) at week 1 and -8.8 ± 5.9 (95% CI -11.2 to -6.4) at week 4 in therapy-naïve patients, and -6.8 ± 5.6 (95% CI -8.0 to -5.5) at week 1 and -9.0 ± 6.1 (95% CI -10.4 to -7.6) at week 4 in add-on therapy patients. Significant improvements from baseline to both week 1 and week 4 were observed in the overall population for all of the examined UPDRS III items (P\0.001). The mean HY score at baseline was significantly higher in the add-on therapy group than in the therapy-naive subgroup (2.40 and 1.90, respectively; P = 0.021). A significant decrease in mean HY score from baseline to week 1 and week 4 (P\0.0001 at any time) was observed in the overall sample, as well as in therapy-naïve and in add-on therapy patients. The extent of the improvement from baseline was more marked in add-on therapy patients than in therapy-naïve patients. The mean (±SD) change from baseline in the overall sample was -0.40 ± 0.58 (95% CI -0.51 to -0.29) at week 1 and -0.67 ± 0.61 (95% CI -0.81 to -0.53) at week 4. Changes from baseline were -0.23 ± 0.32 (95% CI -0.36.4 to -0.10) at week 1 and -0.46 ± 0.48 (95% CI -0.66 to -0.26) at week 4 in therapy-naïve patients, and -0.46 ± 0.64 (95% CI -0.60 to -0.31) at week 1 and -0.74 ± 0.76 (95% CI -0.91 to -0.57) at week 4 in add-on therapy patients.
Rapid Efficacy of Rasagiline on Motor
In the analysis by age, based on median value (B or[71 years), the mean UPDRS III total score at baseline was significantly higher in patients aged [71 years than in the younger cohort (25.9 and 19.0, respectively; P = 0.001).
The mean UPDRS III total score significantly decreased from baseline to both week 1 and week 4 in both subgroups (P\0.0001): the mean decrease from baseline was slightly higher in older patients than in the younger cohort (-7.7 ± 6.2 vs. -5.8 ± 3.2 at Week, and -10.0 ± 7.0 vs. -7.9 ± 4.8 at week 4). However, the difference between subgroups in percentage change from baseline was not statistically significant at both week 1 (mean difference -2.6%; 95% CI -9.4 to 4.1; P = 0.440) and week 4 (mean difference -4.5; 95% CI -12.5 to 3.4; P = 0.261). As for UPDRS III total score, the mean HY score at baseline was significantly higher in the older than in the younger cohort (2.61 and 1.96, respectively; P\0.001). Significant decreases from baseline in mean HY score were observed in the two subgroups by median age (P\0.0001), with more marked decreases in older than in younger patients (-0.52 ± 0.68 vs. -0.28 ± 0.45 at week 1. and -0.83 ± 0.79 vs. -0.52 ± 0.60 at week 4). There were no statistically significant differences between subgroups at week 1 (mean difference 7.1%; 95% CI -1.0 to 12.5; P = 0.085) or week 4 (mean difference 6.8%; 95% CI -2.1 to 15.8; P = 0.134) in percentage changes from baseline.
In the analysis by gender, the mean decrease from baseline in total UPDRS III score was comparable in males (-6.4 ± 4.6 at week 1 and -9.0 ± 5.9 at week 4) and females (-7.1 ± 6.1 at week 1 and -8.9 ± 6.3 at week 4), while the mean decrease from baseline in mean HY score was slightly higher in females (-0.47 ± 0.75 at week 1 and -0.71 ± 0.79 at week 4) than in males (-0.34 ± 0.38 at week 1 and -0.63 ± 0.64 at week 4). If we evaluate patients who showed a benefit [20% on the UPDRS III, we notice that patients showed an average improvement equal to 30.6% (comparing week 1 with baseline) mean (SD) = -30.64 (17.120) and 41.7% (comparing week 1 with baseline) mean (SD) = -30.64 (17.120) . Considering patients aged [71 years (n = 50), 44 (88.0%) were classed as responders versus 6 (12.0%) nonresponders. In the group of patients aged B71 years (n = 52), 42 (80.8%) were responders versus 10 (19.2%) non-responders (Chi-square P value = 0.315).
Pharmacoeconomic Study of Rasagiline
Hudry et al. [42] conducted a study to evaluate the cost-benefit of rasagiline and entacapone as adjunctive therapy to levodopa compared with Neurol Ther (2014) 3:41- 66 57 levodopa alone in patients with PD and motor fluctuations in Finland. The primary analysis was performed according to the social costs as recommended by International Pharmacoeconomic Finns, taking into account both the direct and the indirect costs. It was also performed in a secondary analysis taking into account only the direct costs [43] .
Model Pharmacoeconomics
The study used a Markov model adapted from a model developed originally by Nuijten [44] and adapted from Palmer [45] . The third condition was that of patients reported as 'dead'. The threshold cutoff of 25% was obtained from a study that showed that the onset of motor fluctuations determines a parallel increase in costs.
In this study, we adopted the structure of 
Basic Analysis
The results and average costs and their SD were calculated according to a stochastic approach (Monte Carlo simulation with 10,000 iterations) with prior distributions to take account of the variability in each parameter [46] . The distribution of the results was drawn up on the basis of 10,000 iterations. The incremental cost-effectiveness ratio (ICER) was calculated in the absence of dominance (i.e., better efficiency and less cost).
Sensitivity Analysis
The multivariate probabilistic approach used in this study took into account the uncertainty related to all variables. The best and worst case scenarios were used to test the hypothesis of effectiveness in the standard care group. In the best of cases, patients in the standard care arm could not improve their daily 'off' time in cycle 1 or any additional cycles. At worst, patients in the standard care arm could improve their daily 'off' time in cycles 1-3, just as for patients in the active treatment arm. This approach was the most prudent for treatment with rasagiline from a methodological point of view, but less likely from a clinical point of view. Another sensitivity analysis was to vary the price of rasagiline through a decrease or an increase in percentage of the price of entacapone to assess the impact of a price difference between the two drugs on cost-effectiveness.
Results
During the evaluation period of 2 years, over the other, as they were more effective but also more expensive compared with standard therapy (additional costs of €2,000). Decreasing the price of rasagiline by 20% compared to the price of entacapone has resulted in a cost saving from €930 to €1,500 per patient over 2 years compared with standard care. The price increase of 10% compared with entacapone also showed a cost saving of €300 compared with standard treatment. 
Conclusions
DISCUSSION
The main clinical support for the use of rasagiline arises from three large-scale studies, investigating rasagiline as monotherapy in patients with early PD (TEMPO) and as adjunct therapy (to levodopa) in patients with moderate to advanced PD (PRESTO and LARGO).
In the 6-month, placebo-controlled TEMPO study, rasagiline significantly improved PD symptoms (including specific measures of motor function, ADL, tremor, and bradykinesia), and positively affected overall illness severity and patient QoL [11] . The subsequent 6-month active treatment phase of this study indicated that early use of rasagiline may be able to delay symptom progression [35] , with the beneficial effect of early treatment maintained for up to 6.5 years in the open-label study extension [36] . Data obtained from the ADAGIO study showed similar results relating to delayed symptom progression [34, 47] .
Rasagiline also significantly improved cardinal motor symptoms, in patients with more advanced disease, and reduced daily 'off' time by up to 0.94 h/day versus placebo in patients experiencing motor fluctuations [23, 24] . In all three pivotal clinical studies, rasagiline was well tolerated and was not associated with any specific safety concerns [11, 23, 24] .
Specifically in the TEMPO study, the change in total UPDRS score between baseline and the week 26 visit showed significant differences between active treatment and placebo. In addition, a higher proportion of patients in the active treatment groups responded to therapy, as judged by their change in total UPDRS score compared with the placebo group.
From The results of the ADAGIO study [34] showed that the group of patients treated early with 1 mg/day rasagiline reached the three clinical end points set. Only two of the end points were achieved with the 2 mg/day dose. It can be deduced from the ADAGIO study that early treatment with rasagiline 1 mg/day guarantees benefits that are not are obtained with delayed treatment, despite the use of the same drug.
These results are consistent with the possibility that rasagiline may have 1 mg/day slowing effects in PD. In post hoc analyses, patients with baseline UPDRS scores in the highest quartile who received either 1 or 2 mg/day rasagiline met all three primary end points. In the subgroup with UPDRS scores in the highest quartile who received rasagiline at a dose of 2 mg/day, patients in the early-start group had less worsening in UPDRS scores from baseline to week 72 than those in the delayed-start group (-3.63 ± 1.72 points, P = 0.04).
In patients with UPDRS scores in the highest quartile at baseline who received rasagiline at a dose of 1 mg/day, those in the early-start group had less worsening in the total UPDRS score from baseline to week 72 than patients in the delayedstart group (-3.40 ± 1.66 points, P = 0.04).
Patients enrolled in the TEMPO study were evaluated in a further trial to test the long-term efficacy, safety, and tolerability of rasagiline in all patients who received rasagiline as monotherapy during the trial and subsequent open-label extension [49] . The cohort of patients who were treated with rasagiline monotherapy for 2 years was older, with lower UPDRS scores on study entry, than those requiring adjunctive dopaminergics in the same time frame. The sequence of starting with rasagiline and adding a DA before turning to levodopa was the most commonly chosen approach to long-term therapy. The high proportion of patients maintained on rasagiline monotherapy in the first 2 years of this trial (46%) suggests that initiating rasagiline therapy in early PD patients offers an efficacious and safe alternative strategy for the use of other dopaminergic treatments for a period of time.
The study by Hauser et al. [35] compared the long-term outcome in patients with early-stage PD in the TEMPO study treated with rasagiline earlier in life with those treated late in PD.
During the extension phase of the study reported here, patients continued to receive rasagiline, and other PD medications could be added and adjusted as necessary. For the entire follow-up period of 6.5 years, the mean difference in change from baseline in total UPDRS scores between early-and delayed-start patients was 2.5 units, corresponding to a mean relative difference of 16%. Similarly, for patients who continued in the study up to database lock, the adjusted mean difference in change in total UPDRS scores was 2.4 units, corresponding to a mean relative difference of 17% in favor of the early-start rasagiline group. This suggests that early treatment with rasagiline may offer clinical benefits compared to a delay of treatment for 6 months, and these benefits may be enduring and apparent even as patients are treated with other PD medications.
The post-marketing observational study presented investigated the efficacy and tolerability of rasagiline (as monotherapy or in combination therapy) in daily clinical practice [37] . Either as monotherapy or in combination therapy, rasagiline improved symptoms of PD, reduced the 'off' time, and improved severities of the classical motor symptoms of PD in 42-62% of patients, which is a clinically meaningful outcome. The severities of nonclassic motor/non-motor symptoms including speech disorder, finger dexterity, and postural stability were improved in 31-58% of patients, with favorable tolerability. These results are consistent with the TEMPO, PRESTO and LARGO studies.
Finally, the cost-utility model of rasagiline in advanced PD [42] demonstrated clinical benefits of rasagiline over standard treatment associated with an increased time spent with little or no motor fluctuations and an increase in QALYs.
Sensitivity analyses showed a greater clinical benefit with rasagiline than with standard treatment. From a social point of view after 2 years, rasagiline as adjunctive therapy to levodopa showed greater efficiency compared with levodopa alone, without additional costs. From the social point of view, rasagiline demonstrated a reduced utilization of healthcare resources as well as a reduction of indirect costs and, therefore, potential cost savings. The results of this study support the use of rasagiline as an alternative to levodopa in patients with PD and motor fluctuations. Even with a different mechanism of action, rasagiline was an alternative therapeutic agent to entacapone at no additional cost to the community.
Neuroprotective Effects
Preclinical studies [49, 50] have shown that MAO-B inhibitors can protect neurons from oxidative stress, apoptosis, and other forms of injury in multiple experimental models. The possibility that rasagiline might have a neuroprotective effect is supported by laboratory studies showing that the drug and its metabolite 1-(R)-aminoindan have antiapoptotic effects and protect neurons from a variety of toxins in various models [51] [52] [53] [54] .
Neuroprotection in these models appears to be related to a propargyl ring incorporated within the rasagiline molecule rather than to MAO-B inhibition [54, 55] . In multiple cell culture and animal models, rasagiline has a proven neuroprotective effect [56] [57] [58] . Rasagiline reduces neuronal loss in animal models of Nmethyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration [59] , oxidative stress [60] , hypoxic injury [53] , cerebral trauma [61] , and amyotrophic lateral sclerosis (ALS) [56] . The MAO-inhibition its propargylamine moiety protects mitochondrial viability and the mitochondrial permeability transition pore by activating Bcl-2 and protein kinase C, and downregulating pro-apoptotic FAS and Bax [54, 55] . Rasagiline also increases nerve growth factor, glial cell-derived neurotrophic factor, and brain-derived neurotrophic factor [62] .
The most likely mechanism of action of rasagiline is through inhibition of MAO-B leading to slower catabolism of endogenous dopamine. However, other mechanisms are also possible. In addition to the effect of MAO-B on dopamine catabolism, rasagiline possesses an aminoindan metabolite with antiparkinsonian properties [63] . Rasagiline has been shown to protect neurons against a range of experimentally induced neuronal injuries [59, 64] in animal models and exert an antiapoptotic effect in cell culture [60] . Another possible mechanism of action of rasagiline is through slowing the rate of loss of dopaminergic neurons. Therefore, the long-term benefit observed with early initiation of rasagiline could be due to a neuroprotective effect.
Cognition Effects
The primary effect of rasagiline is to improve the efficiency of dopaminergic transmission, specifically dopaminergic function in the prefrontal cortex, which is known to be depleted of dopamine early in cognitive impairment, but not in demented patients with PD [65] . Several studies have shown that the MAO-B inhibitor selegiline provides some beneficial effects on cognition and may confer beneficial effects on certain aspects of attention and executive functions in non-demented PD patients with cognitive impairment [66, 67] . Recent studies have also confirmed the effects of rasagiline on cognitive function in cognitively impaired, but not demented patients with PD, suggesting that rasagiline may confer beneficial effects on certain aspects of attention and executive functions in non-demented PD patients with cognitive impairment [68] . 
CONCLUSION
